Does Copegus (ribavirin) cause side effects?
Copegus (ribavirin) is an antiviral drug used in combination with interferon to treat chronic hepatitis C. Although the exact mechanism of its action is unknown, Copegus is thought to interfere with the production and/or action of viral DNA and RNA which are critical to the survival and multiplication of the virus.
Common side effects of Copegus therapy interferon include
- flu-like syndrome (consisting of body aches and pains, fever, chills, headache, and malaise),
- loss of appetite,
- difficulty breathing,
- itching, and
- changes in taste.
Serious side effects of Copegus include
- aggravation of psychiatric conditions or triggering of a psychiatric condition such as depression, psychosis, aggressive behavior, hallucinations, or violent behavior; and
- abnormalities of the thyroid gland.
Drug interactions of Copegus include other antiviral drugs with similar mechanisms of action such as those used to manage HIV infection, because it may cause a condition in which lactic acid accumulates in the blood (lactic acidosis) which can lead to serious medical problems.
Adding Copegus treatment among patients taking azathioprine increases the chance of severe pancytopenia (a reduction in the numbers of all types of blood cells) due to azathioprine.
This occurs because Copegus reduces the breakdown of a harmful chemical produced during the breakdown of azathioprine.
There are no studies of Copegus in pregnant women. Copegus should not be taken by pregnant women. In addition, women who are receiving Copegus therapy should wait at least 6 months after Copegus is stopped before becoming pregnant in order to prevent potential effects of Copegus on the fetus.
Since Copegus may cause abnormalities in sperm, men taking Copegus should avoid attempts to impregnate sexual partners and should wait six months after discontinuing the drug before attempting to impregnate.
Although it is unknown if Copegus passes into breast milk, the potential exists for serious adverse effects from combination therapy. Breastfeeding should be discontinued during treatment with Copegus.
What are the side effects of Copegus (ribavirin)?
The most common side effect seen with the combination of ribavirin and interferon is a flu-like syndrome consisting of:
Other possible side effects that may occur during therapy with ribavirin and interferon are:
- difficulty breathing,
- itching, and
- alterations in taste perception.
The most serious side effect seen with ribavirin is anemia. Careful consideration is advised if ribavirin is used in patients with heart or circulation problems since the anemia may aggravate these conditions.
Ribavirin should be avoided among patients who have severe kidney disease and have lost most of their kidneys' function.
Therapy with ribavirin and interferon may aggravate psychiatric conditions or may trigger a psychiatric condition such as
- aggressive behavior,
- hallucinations, or
- violent behavior.
Patients should be closely monitored for the development of these psychiatric conditions.
Therapy with ribavirin and interferon has caused abnormalities of the thyroid gland. If these abnormalities persist and cannot be controlled by medication, it may be necessary to discontinue therapy.
Copegus (ribavirin) side effects list for healthcare professionals
Pegasys in combination with Copegus causes a broad variety of serious adverse reactions. The most common serious or life-threatening adverse reactions induced or aggravated by Copegus/Pegasys include
- relapse of drug abuse/overdose, and
- bacterial infections each occurring at a frequency of less than 1%.
Hepatic decompensation occurred in 2% (10/574) CHC/HIV patients.
Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In the pivotal registration trials NV15801 and NV15942, 886 patients received Copegus for 48 weeks at doses of 1000/1200 mg based on body weight.
In these trials, one or more serious adverse reactions occurred in 10% of CHC monoinfected subjects and in 19% of CHC/HIV subjects receiving Pegasys alone or in combination with Copegus. The most common serious adverse event (3% in CHC and 5% in CHC/HIV) was bacterial infection (e.g., sepsis, osteomyelitis, endocarditis, pyelonephritis, pneumonia).
Other serious adverse reactions occurred at a frequency of less than 1% and included:
- suicidal ideation,
- drug abuse and drug overdose,
- hepatic dysfunction,
- fatty liver,
- diabetes mellitus,
- autoimmune phenomena (e.g., hyperthyroidism, hypothyroidism, sarcoidosis, systemic lupus erythematosus, rheumatoid arthritis),
- peripheral neuropathy,
- aplastic anemia,
- peptic ulcer,
- gastrointestinal bleeding,
- corneal ulcer,
- pulmonary embolism,
- cerebral hemorrhage,
- thrombotic thrombocytopenic purpura,
- psychotic disorder, and
The percentage of patients in clinical trials who experienced one or more adverse events was 98%. The most commonly reported adverse reactions were
- psychiatric reactions,
- including depression,
- anxiety, and flu-like symptoms such as fatigue, pyrexia, myalgia, headache and rigors.
Other common reactions were
Table 5 shows rates of adverse events occurring in greater than or equal to 5% of subjects receiving pegylated interferon and ribavirin combination therapy in the CHC Clinical Trial, NV15801.
- Ten percent of CHC monoinfected patients receiving 48 weeks of therapy with Pegasys in combination with Copegus discontinued therapy; 16% of CHC/HIV coinfected patients discontinued therapy. The most common reasons for discontinuation of therapy were psychiatric, flu-like syndrome (e.g., lethargy, fatigue, headache), dermatologic and gastrointestinal disorders, and laboratory abnormalities (thrombocytopenia, neutropenia, and anemia).
- Overall 39% of patients with CHC or CHC/HIV required modification of Pegasys and/or Copegus therapy. The most common reason for dose modification of Pegasys in CHC and CHC/HIV patients was for laboratory abnormalities; neutropenia (20% and 27%, respectively) and thrombocytopenia (4% and 6%, respectively). The most common reason for dose modification of Copegus in CHC and CHC/HIV patients was anemia (22% and 16%, respectively).
- Pegasys dose was reduced in 12% of patients receiving 1000 mg to 1200 mg Copegus for 48 weeks and in 7% of patients receiving 800 mg Copegus for 24 weeks. Copegus dose was reduced in 21% of patients receiving 1000 mg to 1200 mg Copegus for 48 weeks and in 12% of patients receiving 800 mg Copegus for 24 weeks.
- Chronic hepatitis C monoinfected patients treated for 24 weeks with Pegasys and 800 mg Copegus were observed to have lower incidence of serious adverse events (3% vs. 10%), hemoglobin less than 10 g/dL (3% vs. 15%), dose modification of Pegasys (30% vs. 36%) and Copegus (19% vs. 38%), and of withdrawal from treatment (5% vs. 15%) compared to patients treated for 48 weeks with Pegasys and 1000 mg or 1200 mg Copegus.
- On the other hand, the overall incidence of adverse events appeared to be similar in the two treatment groups.
Table 5 : Adverse Reactions Occurring in greater than or equal to 5% of Patients in Chronic Hepatitis C Clinical Trials (Study NV15801)
|Body System||CHC Combination Therapy Study NV15801|
|Pegasys 180 mcg + 1000 mg or 1200 mg Copegus 48 weeks|
|Intron A + 1000 mg or 1200 mg Rebetol® 48 weeks|
N =443 %
|Application Site Disorders|
|Injection site reaction||23||16|
|Flu-like Symptoms and Signs|
|Metabolic and Nutritional|
|Musculoskeletal, Connective Tissue and Bone|
|Dizziness (excluding vertigo)||14||14|
|Resistance Mechanism Disorders|
|Respiratory, Thoracic and Mediastinal|
|Skin and Subcutaneous Tissue|
|* Severe hematologic abnormalities (lymphocyte less than 500 cells/mm³; hemoglobin less than 10 g/dL; neutrophil less than 750 cells/mm³; platelet less than 50,000 cells/mm³).|
In a clinical trial with 114 pediatric subjects (5 to 17 years of age) treated with Pegasys alone or in combination with Copegus, dose modifications were required in approximately one-third of subjects, most commonly for neutropenia and anemia. In general, the safety profile observed in pediatric subjects was similar to that seen in adults.
In the pediatric study, the most common adverse events in subjects treated with combination therapy Pegasys and Copegus for up to 48 weeks were
- influenza-like illness (91%),
- upper respiratory tract infection (60%),
- headache (64%),
- gastrointestinal disorder (56%),
- skin disorder (47%), and
- injection-site reaction (45%).
Seven subjects receiving combination Pegasys and Copegus treatment for 48 weeks discontinued therapy for safety reasons (depression, psychiatric evaluation abnormal, transient blindness, retinal exudates, hyperglycemia, type 1 diabetes mellitus, and anemia). Severe adverse events were reported in 2 subjects in the Pegasys plus Copegus combination therapy group (hyperglycemia and cholecystectomy).
Table 6 : Percentage of Pediatric Subjects with Adverse Reactions* During First 24 Weeks of Treatment by Treatment Group and for 24 Weeks Post-treatment (in at Least 10% of Subjects)
|System Organ Class||Study NV17424|
|Pegasys 180 mcg/1.73 m² x BSA + Copegus 15 mg/kg|
|Pegasys 180 mcg/1.73 m² x BSA + Placebo**|
|General disorders and administration site conditions|
|Influenza like illness||91||81|
|Injection site reaction||44||42|
|Nervous system disorders|
|Skin and subcutaneous tissue disorders|
|Musculoskeletal, connective tissue and bone disorders|
|Metabolism and nutrition disorders|
|* Displayed adverse drug reactions include all grades of reported adverse clinical events considered possibly, probably, or definitely related to study drug.|
**Subjects in the Pegasys plus placebo arm who did not achieve undetectable viral load at week 24 switched to combination treatment thereafter. Therefore, only the first 24 weeks are presented for the comparison of combination therapy with monotherapy.
In pediatric subjects randomized to combination therapy, the incidence of most adverse reactions was similar for the entire treatment period (up to 48 weeks plus 24 weeks follow-up) in comparison to the first 24 weeks, and increased only slightly for headache, gastrointestinal disorder, irritability and rash. The majority of adverse reactions occurred in the first 24 weeks of treatment.
Growth Inhibition in Pediatric Subjects
- Pediatric subjects treated with Pegasys plus ribavirin combination therapy showed a delay in weight and height increases with up to 48 weeks of therapy compared with baseline.
- Both weight for age and height for age z-scores as well as the percentiles of the normative population for subject weight and height decreased during treatment.
- At the end of 2 years follow-up after treatment, most subjects had returned to baseline normative curve percentiles for weight (64th mean percentile at baseline, 60th mean percentile at 2 years post-treatment) and height (54th mean percentile at baseline, 56th mean percentile at 2 years post-treatment).
- At the end of treatment, 43% (23 of 53) of subjects experienced a weight percentile decrease of more than 15 percentiles, and 25% (13 of 53) experienced a height percentile decrease of more than 15 percentiles on the normative growth curves.
- At 2 years post-treatment, 16% (6 of 38) of subjects were more than 15 percentiles below their baseline weight curve and 11% (4 of 38) were more than 15 percentiles below their baseline height curve.
- Thirty-eight of the 114 subjects enrolled in the long-term follow-up study, extending up to 6 years posttreatment. For most subjects, post-treatment recovery in growth at 2 years post-treatment was maintained to 6 years post-treatment.
Common Adverse Reactions in CHC with HIV Coinfection (Adults)
The adverse event profile of coinfected patients treated with Pegasys/Copegus in Study NR15961 was generally similar to that shown for monoinfected patients in Study NV15801 (Table 5).
Events occurring more frequently in coinfected patients were
- neutropenia (40%),
- anemia (14%),
- thrombocytopenia (8%),
- weight decrease (16%), and
- mood alteration (9%).
Laboratory Test Abnormalities
Anemia due to hemolysis is the most significant toxicity of ribavirin therapy. Anemia (hemoglobin less than 10 g/dL) was observed in 13% of all Copegus and Pegasys combination-treated patients in clinical trials. The maximum drop in hemoglobin occurred during the first 8 weeks of initiation of ribavirin therapy.
Table 7 : Selected Laboratory Abnormalities During Treatment with Copegus in Combination With Either Pegasys or Intron A
|Laboratory Parameter||Pegasys + Ribavirin 1000/1200 mg 48 wks|
|Intron A + Ribavirin 1000/1200 mg 48 wks|
|1,000 < 1,500||34%||38%|
|500 < 1,000||49%||21%|
|50,000 - < 75,000||11%||4%|
|20,000 - < 50,000||5%||< 1%|
|< 8.5||2%||< 1%|
Decreases in hemoglobin, neutrophils and platelets may require dose reduction or permanent discontinuation from treatment. Most laboratory abnormalities noted during the clinical trial returned to baseline levels shortly after discontinuation of treatment.
Table 8 : Selected Hematologic Abnormalities During First 24 Weeks of Treatment by Treatment Group in Previously Untreated Pediatric Subjects
|Laboratory Parameter||Pegasys 180 mcg/1.73 m² x BSA + Copegus 15 mg/kg|
|Pegasys 180 mcg/1.73 m² x BSA + Placebo*|
|1,000 - < 1,500||31%||39%|
|750 - < 1,000||27%||17%|
|500 - < 750||25%||15%|
|75,000 - < 100,000||4%||2%|
|50,000 - < 75,000||0%||2%|
|8.5 - < 10||7%||3%|
|* Subjects in the Pegasys plus placebo arm who did not achieve undetectable viral load at week 24 switched to combination treatment thereafter. Therefore, only the first 24 weeks are presented for the comparison of combination therapy with monotherapy.|
In patients randomized to combination therapy, the incidence of abnormalities during the entire treatment phase (up to 48 weeks plus 24 weeks follow-up) in comparison to the first 24 weeks increased slightly for neutrophils between 500 and 1,000 cells/mm³ and hemoglobin values between 8.5 and 10 g/dL. The majority of hematologic abnormalities occurred in the first 24 weeks of treatment.
The following adverse reactions have been identified and reported during post-approval use of Pegasys/Copegus combination therapy. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and Lymphatic System Disorders
Pure red cell aplasia
Ear and Labyrinth Disorders
Serous retinal detachment
Liver and renal graft rejection
Metabolism and Nutrition Disorders
Skin and Subcutaneous Tissue Disorders
Stevens-Johnson Syndrome (SJS)
Toxic epidermal necrolysis (TEN)
What drugs interact with Copegus (ribavirin)?
Results from a pharmacokinetic sub-study demonstrated no pharmacokinetic interaction between Pegasys (peginterferon alfa-2a) and ribavirin.
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.
- However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n=18), stavudine (n=10), or zidovudine (n=6) were co-administered as part of a multi-drug regimen to HCV/HIV coinfected patients.
- In Study NR15961 among the CHC/HIV coinfected cirrhotic patients receiving NRTIs, cases of hepatic decompensation (some fatal) were observed.
- Patients receiving Pegasys/Copegus and NRTIs should be closely monitored for treatment-associated toxicities.
- Physicians should refer to prescribing information for the respective NRTIs for guidance regarding toxicity management.
- In addition, dose reduction or discontinuation of Pegasys, Copegus or both should also be considered if worsening toxicities are observed, including hepatic decompensation (e.g., Child-Pugh greater than or equal to 6).
- Co-administration of Copegus and didanosine is contraindicated.
- Didanosine or its active metabolite (dideoxyadenosine 5'-triphosphate) concentrations are increased when didanosine is co-administered with ribavirin, which could cause or worsen clinical toxicities.
- Reports of fatal hepatic failure as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials.
- In Study NR15961, patients who were administered zidovudine in combination with Pegasys/Copegus developed severe neutropenia (ANC less than 500) and severe anemia (hemoglobin less than 8 g/dL) more frequently than similar patients not receiving zidovudine (neutropenia 15% vs. 9%) (anemia 5% vs. 1%).
- Discontinuation of zidovudine should be considered as medically appropriate.
Drugs Metabolized By Cytochrome P450
- In vitro studies indicate that ribavirin does not inhibit CYP 2C9, CYP 2C19, CYP 2D6 or CYP 3A4.
- The use of ribavirin to treat chronic hepatitis C in patients receiving azathioprine has been reported to induce severe pancytopenia and may increase the risk of azathioprine-related myelotoxicity. Inosine monophosphate dehydrogenase (IMDH) is required for one of the metabolic pathways of azathioprine.
- Ribavirin is known to inhibit IMDH, thereby leading to accumulation of an azathioprine metabolite, 6-methylthioinosine monophosphate (6-MTITP), which is associated with myelotoxicity (neutropenia, thrombocytopenia, and anemia).
- Patients receiving azathioprine with ribavirin should have complete blood counts, including platelet counts, monitored weekly for the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage or other therapy changes are necessary.
Copegus (ribavirin) is an antiviral drug used in combination with interferon to treat chronic hepatitis C. Common side effects of Copegus therapy interferon include flu-like syndrome (consisting of body aches and pains, fever, chills, headache, and malaise), fatigue, weakness, nausea, loss of appetite, heartburn, insomnia, irritability, difficulty breathing, rash, itching, and changes in taste. There are no studies of Copegus in pregnant women. Copegus should not be taken by pregnant women. Breastfeeding should be discontinued during treatment with Copegus.
Multimedia: Slideshows, Images & Quizzes
Hepatitis C, Hep B, Hep A: Symptoms, Causes, Treatment
Hepatitis C, B, and A are viruses that cause liver inflammation. Hepatitis B vaccines and hepatitis A vaccines are available....
Liver Health: 14 Best and Worst Foods for Your Liver
Get some simple diet tips to keep your liver healthy, including the best veggies to keep disease away and some snacks you'll want...
Hepatitis: Surprising Things That Can Damage Your Liver
Alcohol and acetaminophen are well-known liver dangers, but what else can be harmful? WebMD says some of them may surprise you.
Hepatitis C (Hep C) Symptoms and Treatment
What is Hepatitis C (Hep C, HVC)? Learn about hepatitis c symptoms, how you get hepatitis c, contagiousness, and hepatitis C...
Hepatitis: How Do You Get Hepatitis A, B, and C?
Hepatitis C virus and hepatitis B can make an infected person very sick and they are risk factors for liver cancer, liver...
Hepatitis A Quiz: Test Your Medical IQ
How many types of hepatitis are there, and what is different about hepatitis A? Take this quiz to find out!
Hepatitis C Quiz: What is Hepatitis C?
How many Americans have hepatitis C? Take this quiz to learn the facts about this chronic disease.
Picture of Hepatitis B
Inflammation of the liver due to the hepatitis B virus (HBV), once thought to be passed only through blood products. See a...
Related Disease Conditions
Hepatitis (Viral Hepatitis A, B, C, D, E, G)
Hepatitis is most often viral, due to infection with one of the hepatitis viruses (A, B, C, D, E, F (not confirmed), and G) or another virus (such as those that cause infectious mononucleosis, cytomegalovirus disease). The main nonviral causes of hepatitis are alcohol and drugs. Many patients infected with hepatitis A, B, and C have few or no symptoms of illness. For those who do develop symptoms of viral hepatitis, the most common are flu-like symptoms including: loss of appetite, nausea, vomiting, fever, weakness, tiredness, and aching in the abdomen. Treatment of viral hepatitis is dependent on the type of hepatitis.
Hepatitis C (HCV, Hep C)
Hepatitis C is an inflammation of the liver due to the hepatitis C virus (HCV), which is usually spread by blood transfusion, hemodialysis, and needle sticks, especially with intravenous drug abuse. Symptoms of chronic hepatitis include fatigue, fever, muscle aches, loss of appetite, and fever. Chronic hepatitis C may be cured in most individuals with drugs that target specific genomes of hepatitis C.
Hepatitis A (HAV, Hep A)
Hepatitis means inflammation of the liver. Hepatitis A (HAV, Hep A) is one type of liver disease caused by a virus. Since hepatitis A is a virus, it can pass from person to person from eating or drinking contaminated food or coming into contact with contaminated materials containing the virus. Symptoms of hepatitis A include stomach pain, diarrhea, dark yellow urine, jaundice, and more. There is a vaccine to prevent contracting hepatitis A.
Is Hepatitis C Contagious?
Hepatitis C or hep C causes acute and chronic liver disease. Hep C is a form of liver disease with symptoms like fatigue, jaundice, nausea and vomiting, anorexia, and abdominal discomfort. Hepatitis C is a contagious viral infection caused by persons sharing drug needles, surgical instruments that have not been properly sanitized, and organ transplantation.
Hepatitis B (HBV, Hep B)
The hepatitis B virus (HBV, hep B) is a unique, coated DNA virus belonging to the Hepadnaviridae family of viruses. The course of the virus is determined primarily by the age at which the infection is acquired and the interaction between the virus and the body's immune system. Successful treatment is associated with a reduction in liver injury and fibrosis (scarring), a decreased likelihood of developing cirrhosis and its complications, including liver cancer, and a prolonged survival.
Hepatitis C Cure (Symptoms, Transmission, Treatments, and Cost)
Hepatitis is inflammation of the liver. There are a variety of toxins, diseases, illicit drugs, medications, bacterial and viral infections, and heavy alcohol use can case inflammation of the liver. Hepatitis C viral infection (HCV) is one type of hepatitis. According to the CDC, in 2014 there were an estimated 30,500 cases of acute hepatitis C infections in the US. An estimated 2.7-3.9 million people in the US have chronic hepatitis C. The virus is spread from person-to-person via blood-to-blood contact. Symptoms of HCV infection include joint pain, jaundice, dark urine, nausea, fatigue, fever, loss of appetites, clay colored stool. Hepatitis C can be cured with medications in most people. There is no vaccine against the hepatitis C virus.
Hepatitis A and B Vaccinations
Hepatitis A and hepatitis B are the two most commnon viruses that infect the liver. Hepatitis A and Hepatitis B can be prevented and treated with immunizations (vaccinations) such as Havrix, Vaqta, Twinrix, Comvax, Pediarix, and hepatitis b immune globulin (HBIG).
Is Hepatitis Contagious?
Hepatitis means "inflammation of the liver," and there are several different types of such as A, B, C, D, and E. Some types of hepatitis are contagious and some types are not. Hepatitis symptoms vary upon the type of disease; however, the following symptoms may develop in someone with hepatitis: fatigue, nausea and vomiting, abdominal pain and discomfort, jaundice (yellowing of the skin and whites of the eyes), and loss of appetite. Treatment for hepatitis depends upon the cause. Some types of hepatitis have a vaccine to prevent spread of disease such as hepatitis A and B.
Is Hepatitis B Contagious?
Hepatitis B is a type of liver infection. Hepatitis B is spread through person-to-person contact or through personal items like razors, toothbrushes, etc. Symptoms of hepatitis B include fever, yellowish skin (jaundice), dark urine, fatigue, nausea, and vomiting. There is no drug to cure hepatitis B; however, there is a hepatitis B vaccine available.
Is Hepatitis A Contagious?
Hepatitis means inflammation of the liver. Hepatitis A is one type of hepatitis. Hepatitis is transmitted through person to person contact, contaminated ice, vegetables, fruits, and untreated water. Hepatitis A can be prevented by the hepatitis A vaccine. Symptoms of hepatitis A may include nausea and/or vomiting, fever, loss of appetite, abdominal pain, dark urine, clay-colored stools, jaundice (yellowish color to skin and/or eyes, or joint pain.
Hepatitis E Viral Infection
Hepatitis E (hep E) is a type of hepatitis viral infection that includes hepatitis A, B, C, D, F, which is caused by the hepatitis E virus. Usually, you get (transmitted) hepatitis E from eating or drinking dirty or contaminated water. Hepatitis E can be very serious, especially if a woman is pregnant. Up to ¼ of women who are pregnant with the hep E virus can die from the infection. The signs and symptoms of hepatitis E infection are nausea and vomiting, brown or dark urine, stool changes jaundice (yellow eyes and skin), pain in the right side of the abdomen, dark or brown urine, and light-colored stool. Some people with hep E don’t have any symptoms so they don’t know that they are contagious. It takes about 6 weeks to recover from hep E. A person who has any type of hepatitis, including hepatitis E, should not drink any alcohol. Hep E complications are rare, but when they do occur they include severe (“fulminant”) hepatitis, liver failure, and death. Currently, no specific drugs or treatments are available for hepatitis E. Moreover, the only hepatitis E vaccine currently is available in China. Avoid alcohol, keep hydrated, and getting rest are home remedies for hepatitis E. Talk to your doctor before taking any over-the-counter (medications), especially those containing acetaminophen (Tylenol and others). Usually, the prognosis and life expectancy for hepatitis E after recovery is good. Most people do not have long term liver problems from the infection.
Treatment & Diagnosis
- Hepatitis C FAQs
- Hepatitis A FAQs
- Hepatitis C: Nightmare in Vegas
- Hepatitis C News Release
- Chronic Viral Hepatitis, Alcoholism, Cirrhosis Linked to Liver Cancer
- Hepatitis A at Jam Band Concerts Alert
- IBS, GERD, Hepatitis C: Doctors Dialogue
- How common is Hepatitis C?
- How is diagnosis of Hepatitis C made?
- Hepatitis C : Can it be sexually transmitted?
- Hepatitis C: What blood tests?
- Hepatitis C genotypes
- Hepatitis C Treatments
- Hepatitis C: Most effective treatment
- Hepatitis C: Reasons for treating
- Hepatitis C: Interferon/ribavarin side effects
- Hepatitis C: Good candidates for treatment
- Do you treat hepatitis C patients with normal liver tests?
- Hepatitis C: Not Good Candidates for Treatment?
- Hepatitis C: Diet and Vitamins
- Hepatitis C: Should patients receive immunizations
- Hepatitis C treatment relapse
- What to do for relapsers after hepatitis C treatment?
- Hepatitis C: What is unique about hepatitis C?
- Can You Be Allergic to Ceclor for Hepatitis B?
- Can You Treat Hepatitis B With Aids Drug Lamivudine?
- Does Hepatitis B Cause Liver Cancer?
- What Kind of Doctor Do I See for Hepatitis C?
- Can The Hepatitis C Virus Survive Outside the Body?
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.